---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-029558"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:13:52.966024+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rigel reports Q4 2022 net income $1.4M on record TAVALISSE sales of $21.9M; full year revenue $120.2M

## Summary
- Q4 total revenue $51.3M ($21.9M TAVALISSE + $0.9M REZLIDHIA); net income $1.4M ($0.01/share) vs net loss $22.6M in Q4'21.
- Full year 2022 net loss $58.6M ($0.34/share) on revenue $120.2M, compared to net loss $17.9M in 2021.
- TAVALISSE 2022 net product sales $75.8M, up 20% YoY; Q4 bottles shipped to patients/clinics a record.
- REZLIDHIA launched in Dec '22, $0.9M in Q4 sales; added to NCCN Guidelines for AML in Jan '23.
- Cash and investments $58.2M at Dec 31, 2022, down from $125.0M at Dec 31, 2021.

## SEC filing metadata
- accession: 0001104659-23-029558
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465923029558/0001104659-23-029558-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465923029558/tm238702d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-029558
- JSON: https://secwatch.observer/filing/0001104659-23-029558.json
- Plain text: https://secwatch.observer/filing/0001104659-23-029558.txt

## Key facts
- Earnings Releases
  RIGEL PHARMACEUTICALS INC reported fourth quarter and year ended December 31, 2022 results: revenue $51.3 million, net income $1.4 million, or $0.01 per basic and diluted share, EPS $0.01 per basic and diluted share.
  - Period: fourth quarter and year ended December 31, 2022
  - Revenue: $51.3 million
  - Net income: $1.4 million, or $0.01 per basic and diluted share
  - EPS: $0.01 per basic and diluted share
  - Result: reported results
  source text: EXHIBIT 99.1 Exhibit 99.1 Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update ● Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE ® net product sales of $21.9 million and REZLIDHIA TM net product sales of $0.9 million ● REZLIDHIA U.S. commercial launch continues to progress and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465923029558/0001104659-23-029558-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.